董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Edick | 男 | Independent Director and Chairperson of the Board | 64 | 41.27万美元 | 未持股 | 2020-04-01 |
| Debra K. Liebert | 女 | Independent Director | 63 | 26.13万美元 | 未持股 | 2020-04-01 |
| Joseph Oliveto | 男 | President, Chief Executive Officer and Director | 52 | 78.50万美元 | 未持股 | 2020-04-01 |
| Richard Pasternak | 男 | Independent Director | 71 | 24.13万美元 | 未持股 | 2020-04-01 |
| Paul Truex | 男 | Independent Director | 51 | 8.57万美元 | 未持股 | 2020-04-01 |
| Michael Tomsicek | 男 | Independent Director | 54 | 22.40万美元 | 未持股 | 2020-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lorenz Muller | 男 | Chief Commercial Officer | 56 | 64.57万美元 | 未持股 | 2020-04-01 |
| Francis Plat | 男 | Chief Medical Officer | 62 | 57.91万美元 | 未持股 | 2020-04-01 |
| Joseph Oliveto | 男 | President, Chief Executive Officer and Director | 52 | 78.50万美元 | 未持股 | 2020-04-01 |
| Amit Hasija | 男 | Chief Financial Officer and Executive Vice President of Corporate Development | 47 | 246.33万美元 | 未持股 | 2020-04-01 |
董事简历
中英对照 | 中文 | 英文- Paul Edick
-
Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006. - Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
- Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006.
- Debra K. Liebert
-
DebraK.Liebert自2015年6月起担任董事会成员。Liebert女士于2007年至2019年12月担任Domain Associates，LLC（一家专注于生命科学的梦百合风险投资公司）的负责人，并于2014年1月至2019年12月担任董事总经理。Liebert女士此前曾在Cancervax Corporation，Atairgin Technologies和Trega Biosciences担任多个职位。Liebert女士在克拉里昂大学（Clarion University）获得化学学士学位，在杜肯大学（Duquesne University）获得药理学/毒理学硕士学位，在洛杉矶加利福尼亚大学（University of California）获得工商管理硕士学位。
Debra K. Liebert has served as a member of our Board since June 2015. Ms. Liebert served as a Principal of Domain Associates, LLC, a healthcare venture capital firm with an exclusive focus on life sciences, from 2007 to December 2019 and as a Managing Director from January 2014 to December 2019. Ms. Liebert previously served in various positions at CancerVax Corporation, Atairgin Technologies and Trega Biosciences. Ms. Liebert received her B.S. degree in chemistry from Clarion University, her M.S. degree in pharmacology/toxicology from Duquesne University, and her M.B.A degree from University of California, Los Angeles. - DebraK.Liebert自2015年6月起担任董事会成员。Liebert女士于2007年至2019年12月担任Domain Associates，LLC（一家专注于生命科学的梦百合风险投资公司）的负责人，并于2014年1月至2019年12月担任董事总经理。Liebert女士此前曾在Cancervax Corporation，Atairgin Technologies和Trega Biosciences担任多个职位。Liebert女士在克拉里昂大学（Clarion University）获得化学学士学位，在杜肯大学（Duquesne University）获得药理学/毒理学硕士学位，在洛杉矶加利福尼亚大学（University of California）获得工商管理硕士学位。
- Debra K. Liebert has served as a member of our Board since June 2015. Ms. Liebert served as a Principal of Domain Associates, LLC, a healthcare venture capital firm with an exclusive focus on life sciences, from 2007 to December 2019 and as a Managing Director from January 2014 to December 2019. Ms. Liebert previously served in various positions at CancerVax Corporation, Atairgin Technologies and Trega Biosciences. Ms. Liebert received her B.S. degree in chemistry from Clarion University, her M.S. degree in pharmacology/toxicology from Duquesne University, and her M.B.A degree from University of California, Los Angeles.
- Joseph Oliveto
-
Joseph Oliveto自2017年3月起担任公司总裁兼首席执行官，自2017年7月起担任董事会成员。在成为我们的总裁兼首席执行官之前，Oliveto先生于2016年至2017年3月担任公司顾问。Oliveto先生于2015年7月至2016年6月担任Galleon Pharmaceuticals，Inc.的首席执行官。2008年6月至2014年6月，奥利维托曾在Chelsea TherapeuticsInternational，Ltd.担任多个职位，包括2014年1月至2014年6月担任总裁兼首席执行官，以及董事会成员，负责监督该公司出售给Lundbeck，Inc.的交易，此后，他于2014年7月至2015年7月担任执行顾问。Oliveto先生在罗格斯大学（Rutgers University）获得化学学士学位和工商管理硕士学位。
Joseph Oliveto has served as our President and Chief Executive Officer since March 2017 and as a member of our Board since July 2017. Prior to becoming our President and Chief Executive Officer, Mr. Oliveto served as a consultant to the company from 2016 to March 2017. Mr. Oliveto served as Chief Executive Officer at Galleon Pharmaceuticals, Inc. from July 2015 to June 2016. From June 2008 to June 2014 Mr. Oliveto was at Chelsea Therapeutics International, Ltd., where he held various roles, including serving as President and Chief Executive Officer and a member of the board of directors from January 2014 to June 2014 overseeing the company's sale to Lundbeck, Inc., following which he served as an Executive Advisor from July 2014 to July 2015. Mr. Oliveto received his B.A. degree in Chemistry and his M.B.A. degree from Rutgers University. - Joseph Oliveto自2017年3月起担任公司总裁兼首席执行官，自2017年7月起担任董事会成员。在成为我们的总裁兼首席执行官之前，Oliveto先生于2016年至2017年3月担任公司顾问。Oliveto先生于2015年7月至2016年6月担任Galleon Pharmaceuticals，Inc.的首席执行官。2008年6月至2014年6月，奥利维托曾在Chelsea TherapeuticsInternational，Ltd.担任多个职位，包括2014年1月至2014年6月担任总裁兼首席执行官，以及董事会成员，负责监督该公司出售给Lundbeck，Inc.的交易，此后，他于2014年7月至2015年7月担任执行顾问。Oliveto先生在罗格斯大学（Rutgers University）获得化学学士学位和工商管理硕士学位。
- Joseph Oliveto has served as our President and Chief Executive Officer since March 2017 and as a member of our Board since July 2017. Prior to becoming our President and Chief Executive Officer, Mr. Oliveto served as a consultant to the company from 2016 to March 2017. Mr. Oliveto served as Chief Executive Officer at Galleon Pharmaceuticals, Inc. from July 2015 to June 2016. From June 2008 to June 2014 Mr. Oliveto was at Chelsea Therapeutics International, Ltd., where he held various roles, including serving as President and Chief Executive Officer and a member of the board of directors from January 2014 to June 2014 overseeing the company's sale to Lundbeck, Inc., following which he served as an Executive Advisor from July 2014 to July 2015. Mr. Oliveto received his B.A. degree in Chemistry and his M.B.A. degree from Rutgers University.
- Richard Pasternak
-
Richard Pasternak自2019年11月起担任董事会成员。他目前是the Weill Cornell Medical College的临床教授。Pasternak博士于2019年从Cerenis Therapeutics（现为Abionyx Pharma）退休，该公司是一家法国上市公司，专注于开发心血管疾病的治疗方法，他自2011年以来一直担任该公司的首席执行官兼董事会主席。从2004年到2010年，他曾担任默克公司（Merck&Co.）的Vice President、心血管临床研究主管、全球科学事务和科学领导力主管。加入Merck&Co.公司之前，他曾担任Massachusetts General Hospital的预防心脏病和心脏康复董事，以及Harvard Medical School的医学副教授。Pasternak博士还任职于Anthos Therapeutics和Magenta Medical Ltd.的董事会。他此前曾任职Essentialis Therapeutics公司和Haptocure Ltd.的董事会，以及几个非营利组织。他此前也曾担任Bay City Capital and Bridge Medicines公司的高级顾问。Pasternak博士在耶鲁大学（Yale University）获得文学学士学位和医学博士学位，并在马萨诸塞州总医院（Massachusetts General Hospital）完成医学和心脏病学培训。
Richard Pasternak has served as a member of our Board since November 2019. He is currently a Clinical Professor at the Weill Cornell Medical College. In 2019 Dr. Pasternak retired from Cerenis Therapeutics now ABIONYX Pharma, a French publicly-traded company focused on developing treatments for cardiovascular diseases, where he served since 2011 most recently as Chief Executive Officer and Chair of the Board of Directors. He previously served as Vice President, Head of Cardiovascular Clinical Research, and Head of Global Scientific Affairs and Scientific Leadership, at Merck & Co. from 2004 to 2010. Prior to joining Merck & Co., he was the Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Dr. Pasternak also serves on the Boards of Anthos Therapeutics and Magenta Medical Ltd. He previously served on the Boards of Essentialis Therapeutics and Haptocure Ltd., as well as several nonprofit organizations. He was also previously a senior advisor to Bay City Capital and Bridge Medicines. Dr. Pasternak received his BA and MD from Yale University, and completed his medical and cardiology training at Massachusetts General Hospital. - Richard Pasternak自2019年11月起担任董事会成员。他目前是the Weill Cornell Medical College的临床教授。Pasternak博士于2019年从Cerenis Therapeutics（现为Abionyx Pharma）退休，该公司是一家法国上市公司，专注于开发心血管疾病的治疗方法，他自2011年以来一直担任该公司的首席执行官兼董事会主席。从2004年到2010年，他曾担任默克公司（Merck&Co.）的Vice President、心血管临床研究主管、全球科学事务和科学领导力主管。加入Merck&Co.公司之前，他曾担任Massachusetts General Hospital的预防心脏病和心脏康复董事，以及Harvard Medical School的医学副教授。Pasternak博士还任职于Anthos Therapeutics和Magenta Medical Ltd.的董事会。他此前曾任职Essentialis Therapeutics公司和Haptocure Ltd.的董事会，以及几个非营利组织。他此前也曾担任Bay City Capital and Bridge Medicines公司的高级顾问。Pasternak博士在耶鲁大学（Yale University）获得文学学士学位和医学博士学位，并在马萨诸塞州总医院（Massachusetts General Hospital）完成医学和心脏病学培训。
- Richard Pasternak has served as a member of our Board since November 2019. He is currently a Clinical Professor at the Weill Cornell Medical College. In 2019 Dr. Pasternak retired from Cerenis Therapeutics now ABIONYX Pharma, a French publicly-traded company focused on developing treatments for cardiovascular diseases, where he served since 2011 most recently as Chief Executive Officer and Chair of the Board of Directors. He previously served as Vice President, Head of Cardiovascular Clinical Research, and Head of Global Scientific Affairs and Scientific Leadership, at Merck & Co. from 2004 to 2010. Prior to joining Merck & Co., he was the Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Dr. Pasternak also serves on the Boards of Anthos Therapeutics and Magenta Medical Ltd. He previously served on the Boards of Essentialis Therapeutics and Haptocure Ltd., as well as several nonprofit organizations. He was also previously a senior advisor to Bay City Capital and Bridge Medicines. Dr. Pasternak received his BA and MD from Yale University, and completed his medical and cardiology training at Massachusetts General Hospital.
- Paul Truex
-
Paul Truex，自2008年2月起担任董事；自2004年9月起担任Anthera Pharmaceuticals, Inc.（制药公司，由他成立）的总裁兼首席执行官；2001年10月至2004年9月间担任Peninsula Pharmaceuticals, Inc.（生物制药公司）的董事、总裁兼首席执行官；2000年4月至2001年9月间担任Vicuron, Inc.（生物制药公司）的商业发展副总裁；1997年7月至2000年4月间担任Eli Lilly and Company（制药公司）的多个职位。他目前是Anthera Pharmaceuticals, Inc.和Eiger Biopharmaceuticals, Inc.的董事。他获得了Indiana University的营销与金融学工商管理硕士学位，以及the University of Waterloo的经济学学士学位。
Paul Truex has served as a member of our Board since February 2012. From June 2012 to October 2018 Mr. Truex was the Chairman of our Board. Mr. Truex is a founder and Executive Chairman of LQT Therapeutics, Inc. and has served in that role since July 2019. Mr. Truex previously served as Executive Chairman of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Truex was a founder of Anthera where he served as Director and Chief Executive Officer from September 2004 to December 2016. He previously served as the President of Anthera from its inception in September 2004 until January 2016 and as its Chief Executive Officer from September 2004 to December 2016. Prior to founding Anthera, Mr. Truex served as a founder, director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc. from the commencement of its operations in October 2001 until December 2005 after which Peninsula was acquired in a series of transactions by Johnson and Johnson and Forest Laboratories. Mr. Truex is currently a director at CymaBay Therapeutics Inc., a Nasdaq-listed company, where he has served since April 2016. From May 2012 to September 2013 he served on the board of directors of Trius Therapeutics Inc. acquired by Cubist Pharmaceuticals, Inc. in July 2013. Mr. Truex obtained his M.B.A. in marketing and finance from Indiana University and his B.A. in economics from the University of Waterloo. - Paul Truex，自2008年2月起担任董事；自2004年9月起担任Anthera Pharmaceuticals, Inc.（制药公司，由他成立）的总裁兼首席执行官；2001年10月至2004年9月间担任Peninsula Pharmaceuticals, Inc.（生物制药公司）的董事、总裁兼首席执行官；2000年4月至2001年9月间担任Vicuron, Inc.（生物制药公司）的商业发展副总裁；1997年7月至2000年4月间担任Eli Lilly and Company（制药公司）的多个职位。他目前是Anthera Pharmaceuticals, Inc.和Eiger Biopharmaceuticals, Inc.的董事。他获得了Indiana University的营销与金融学工商管理硕士学位，以及the University of Waterloo的经济学学士学位。
- Paul Truex has served as a member of our Board since February 2012. From June 2012 to October 2018 Mr. Truex was the Chairman of our Board. Mr. Truex is a founder and Executive Chairman of LQT Therapeutics, Inc. and has served in that role since July 2019. Mr. Truex previously served as Executive Chairman of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Truex was a founder of Anthera where he served as Director and Chief Executive Officer from September 2004 to December 2016. He previously served as the President of Anthera from its inception in September 2004 until January 2016 and as its Chief Executive Officer from September 2004 to December 2016. Prior to founding Anthera, Mr. Truex served as a founder, director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc. from the commencement of its operations in October 2001 until December 2005 after which Peninsula was acquired in a series of transactions by Johnson and Johnson and Forest Laboratories. Mr. Truex is currently a director at CymaBay Therapeutics Inc., a Nasdaq-listed company, where he has served since April 2016. From May 2012 to September 2013 he served on the board of directors of Trius Therapeutics Inc. acquired by Cubist Pharmaceuticals, Inc. in July 2013. Mr. Truex obtained his M.B.A. in marketing and finance from Indiana University and his B.A. in economics from the University of Waterloo.
- Michael Tomsicek
-
Michael Tomsicek自2022年10月起担任Acrivon Therapeutics，Inc.的董事会成员。自2019年4月以来，Tomsicek先生一直担任在纳斯达克上市的生物制药公司Milestone Pharmaceuticals USA，Inc.的董事会成员。Tomsicek先生于2017年11月至2021年10月在纳斯达克上市的基因编辑公司CRISPR Therapeutics AG担任Chief Financial Officer。在此之前，Tomsicek先生于2015年7月至2017年8月在纳斯达克上市的医疗器械公司Abiomed, Inc.担任Chief Financial Officer。在此之前，他在Cubist Pharmaceuticals，Inc.或Cubist，一家在纳斯达克上市的生物制药公司担任Chief Financial Officer。2010年8月至2015年1月，他在Cubist公司通过公司出售给默克公司任职，并担任过一系列越来越重要的职务，领导财务、投资者关系和战略采购。在加入Cubist之前，Tomsicek先生在通用电气医疗集团工作了近八年，最终担任全球超声业务的Chief Financial Officer。Tomsicek先生拥有威斯康星大学的工商管理硕士学位和工程学学士学位。
Michael Tomsicek,has served as a member of the board of directors of Milestone Pharmaceuticals USA, Inc., a Nasdaq-listed biopharmaceutical company, since April 2019. Mr. Tomsicek served as the Chief Financial Officer of CRISPR Therapeutics AG, a Nasdaq-listed gene editing company, from November 2017 through October 2021. Prior to that, Mr. Tomsicek served as Chief Financial Officer of Abiomed, Inc., a Nasdaq-listed medical device company, from July 2015 to August 2017. Before that, he was Chief Financial Officer at Cubist Pharmaceuticals, Inc., or Cubist, a Nasdaq-listed biopharmaceutical company. He was at Cubist from August 2010 to January 2015, through the company's sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound business. Mr. Tomsicek holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin. - Michael Tomsicek自2022年10月起担任Acrivon Therapeutics，Inc.的董事会成员。自2019年4月以来，Tomsicek先生一直担任在纳斯达克上市的生物制药公司Milestone Pharmaceuticals USA，Inc.的董事会成员。Tomsicek先生于2017年11月至2021年10月在纳斯达克上市的基因编辑公司CRISPR Therapeutics AG担任Chief Financial Officer。在此之前，Tomsicek先生于2015年7月至2017年8月在纳斯达克上市的医疗器械公司Abiomed, Inc.担任Chief Financial Officer。在此之前，他在Cubist Pharmaceuticals，Inc.或Cubist，一家在纳斯达克上市的生物制药公司担任Chief Financial Officer。2010年8月至2015年1月，他在Cubist公司通过公司出售给默克公司任职，并担任过一系列越来越重要的职务，领导财务、投资者关系和战略采购。在加入Cubist之前，Tomsicek先生在通用电气医疗集团工作了近八年，最终担任全球超声业务的Chief Financial Officer。Tomsicek先生拥有威斯康星大学的工商管理硕士学位和工程学学士学位。
- Michael Tomsicek,has served as a member of the board of directors of Milestone Pharmaceuticals USA, Inc., a Nasdaq-listed biopharmaceutical company, since April 2019. Mr. Tomsicek served as the Chief Financial Officer of CRISPR Therapeutics AG, a Nasdaq-listed gene editing company, from November 2017 through October 2021. Prior to that, Mr. Tomsicek served as Chief Financial Officer of Abiomed, Inc., a Nasdaq-listed medical device company, from July 2015 to August 2017. Before that, he was Chief Financial Officer at Cubist Pharmaceuticals, Inc., or Cubist, a Nasdaq-listed biopharmaceutical company. He was at Cubist from August 2010 to January 2015, through the company's sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound business. Mr. Tomsicek holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin.
高管简历
中英对照 | 中文 | 英文- Lorenz Muller
Lorenz Muller自2017年10月起担任我们的首席商务官。在加入我们公司之前，穆勒先生于2016年6月至2017年7月担任分子诊断公司Exact Sciences Corporation的营销Vice President。在此之前，Muller先生于2008年7月至2015年12月担任Daiichi Sankyo，Inc.血栓形成执行董事。Muller先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程与生命科学学士学位和化学工程硕士学位。他在Harvard Graduate School of Business Administration获得工商管理硕士学位。
Lorenz Muller has served as our Chief Commercial Officer since October 2017. Prior to joining our company, Mr. Muller served as the Vice President of Marketing at Exact Sciences Corporation, a molecular diagnostics company, from June 2016 through July 2017. Prior to that, Mr. Muller served as the Executive Director, Thrombosis at Daiichi Sankyo, Inc. from July 2008 through December 2015. Mr. Muller received his B.S. degrees in Chemical Engineering and Life Sciences and his M.S. degree in Chemical Engineering from the Massachusetts Institute of Technology. He received his M.B.A degree from the Harvard Graduate School of Business Administration.- Lorenz Muller自2017年10月起担任我们的首席商务官。在加入我们公司之前，穆勒先生于2016年6月至2017年7月担任分子诊断公司Exact Sciences Corporation的营销Vice President。在此之前，Muller先生于2008年7月至2015年12月担任Daiichi Sankyo，Inc.血栓形成执行董事。Muller先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程与生命科学学士学位和化学工程硕士学位。他在Harvard Graduate School of Business Administration获得工商管理硕士学位。
- Lorenz Muller has served as our Chief Commercial Officer since October 2017. Prior to joining our company, Mr. Muller served as the Vice President of Marketing at Exact Sciences Corporation, a molecular diagnostics company, from June 2016 through July 2017. Prior to that, Mr. Muller served as the Executive Director, Thrombosis at Daiichi Sankyo, Inc. from July 2008 through December 2015. Mr. Muller received his B.S. degrees in Chemical Engineering and Life Sciences and his M.S. degree in Chemical Engineering from the Massachusetts Institute of Technology. He received his M.B.A degree from the Harvard Graduate School of Business Administration.
- Francis Plat
Francis Plat自2015年6月起担任我们的首席医疗官。在加入我们公司之前，Plat博士于2013年8月至2015年5月担任临床顾问。Plat从2009年8月到2013年7月担任Merck Research Laboratories动脉粥样硬化和心血管Vice President和治疗区域主管。在此之前，Plat博士是全球制药公司Daiichi Sankyo，Inc.心血管临床开发的Vice President。Plat博士在巴黎大学（University of Paris）获得医学博士学位，是法国一名获得董事会认证的心脏病学家，在那里他花了10年时间从事医学工作，包括在Hopital Marie Lannelongue的重症监护室进行心血管后手术和在布鲁赛斯医院（Broussais Hospital）进行心脏康复。
Francis Plat has served as our Chief Medical Officer since June 2015. Prior to joining our company, Dr. Plat was a clinical consultant from August 2013 to May 2015. From August 2009 to July 2013 Dr. Plat served as the Vice President and Therapeutic Area Head, Atherosclerosis and Cardiovascular, at Merck Research Laboratories. Prior to that, Dr. Plat was the Vice President of Cardiovascular Clinical Development at Daiichi Sankyo, Inc., a global pharmaceutical company. Dr. Plat received his M.D. from the University of Paris and is a board-certified cardiologist in France, where he spent 10 years practicing medicine, including post-cardiovascular surgery at the intensive care unit in the Hopital Marie Lannelongue and in cardiac rehabilitation at Broussais Hospital.- Francis Plat自2015年6月起担任我们的首席医疗官。在加入我们公司之前，Plat博士于2013年8月至2015年5月担任临床顾问。Plat从2009年8月到2013年7月担任Merck Research Laboratories动脉粥样硬化和心血管Vice President和治疗区域主管。在此之前，Plat博士是全球制药公司Daiichi Sankyo，Inc.心血管临床开发的Vice President。Plat博士在巴黎大学（University of Paris）获得医学博士学位，是法国一名获得董事会认证的心脏病学家，在那里他花了10年时间从事医学工作，包括在Hopital Marie Lannelongue的重症监护室进行心血管后手术和在布鲁赛斯医院（Broussais Hospital）进行心脏康复。
- Francis Plat has served as our Chief Medical Officer since June 2015. Prior to joining our company, Dr. Plat was a clinical consultant from August 2013 to May 2015. From August 2009 to July 2013 Dr. Plat served as the Vice President and Therapeutic Area Head, Atherosclerosis and Cardiovascular, at Merck Research Laboratories. Prior to that, Dr. Plat was the Vice President of Cardiovascular Clinical Development at Daiichi Sankyo, Inc., a global pharmaceutical company. Dr. Plat received his M.D. from the University of Paris and is a board-certified cardiologist in France, where he spent 10 years practicing medicine, including post-cardiovascular surgery at the intensive care unit in the Hopital Marie Lannelongue and in cardiac rehabilitation at Broussais Hospital.
- Joseph Oliveto
Joseph Oliveto自2017年3月起担任公司总裁兼首席执行官，自2017年7月起担任董事会成员。在成为我们的总裁兼首席执行官之前，Oliveto先生于2016年至2017年3月担任公司顾问。Oliveto先生于2015年7月至2016年6月担任Galleon Pharmaceuticals，Inc.的首席执行官。2008年6月至2014年6月，奥利维托曾在Chelsea TherapeuticsInternational，Ltd.担任多个职位，包括2014年1月至2014年6月担任总裁兼首席执行官，以及董事会成员，负责监督该公司出售给Lundbeck，Inc.的交易，此后，他于2014年7月至2015年7月担任执行顾问。Oliveto先生在罗格斯大学（Rutgers University）获得化学学士学位和工商管理硕士学位。
Joseph Oliveto has served as our President and Chief Executive Officer since March 2017 and as a member of our Board since July 2017. Prior to becoming our President and Chief Executive Officer, Mr. Oliveto served as a consultant to the company from 2016 to March 2017. Mr. Oliveto served as Chief Executive Officer at Galleon Pharmaceuticals, Inc. from July 2015 to June 2016. From June 2008 to June 2014 Mr. Oliveto was at Chelsea Therapeutics International, Ltd., where he held various roles, including serving as President and Chief Executive Officer and a member of the board of directors from January 2014 to June 2014 overseeing the company's sale to Lundbeck, Inc., following which he served as an Executive Advisor from July 2014 to July 2015. Mr. Oliveto received his B.A. degree in Chemistry and his M.B.A. degree from Rutgers University.- Joseph Oliveto自2017年3月起担任公司总裁兼首席执行官，自2017年7月起担任董事会成员。在成为我们的总裁兼首席执行官之前，Oliveto先生于2016年至2017年3月担任公司顾问。Oliveto先生于2015年7月至2016年6月担任Galleon Pharmaceuticals，Inc.的首席执行官。2008年6月至2014年6月，奥利维托曾在Chelsea TherapeuticsInternational，Ltd.担任多个职位，包括2014年1月至2014年6月担任总裁兼首席执行官，以及董事会成员，负责监督该公司出售给Lundbeck，Inc.的交易，此后，他于2014年7月至2015年7月担任执行顾问。Oliveto先生在罗格斯大学（Rutgers University）获得化学学士学位和工商管理硕士学位。
- Joseph Oliveto has served as our President and Chief Executive Officer since March 2017 and as a member of our Board since July 2017. Prior to becoming our President and Chief Executive Officer, Mr. Oliveto served as a consultant to the company from 2016 to March 2017. Mr. Oliveto served as Chief Executive Officer at Galleon Pharmaceuticals, Inc. from July 2015 to June 2016. From June 2008 to June 2014 Mr. Oliveto was at Chelsea Therapeutics International, Ltd., where he held various roles, including serving as President and Chief Executive Officer and a member of the board of directors from January 2014 to June 2014 overseeing the company's sale to Lundbeck, Inc., following which he served as an Executive Advisor from July 2014 to July 2015. Mr. Oliveto received his B.A. degree in Chemistry and his M.B.A. degree from Rutgers University.
- Amit Hasija
Amit Hasija自2019年9月起担任公司发展首席财务官兼执行Vice President。在加入Milestone Pharmaceuticals之前，Hasija先生曾担任Fulcrum Therapeutics的首席财务官和首席商务官。任职Fulcrum公司之前，他曾任职Sanofi公司5年，最近担任Integrated Care公司的Vice President。在赛诺菲，他还担任北美制药业务发展的Vice President。在加入赛诺菲之前，Hasija先生在瑞士信贷（Credit Suisse），高盛（Goldman Sachs）和德意志银行（Deutsche Bank）担任投资银行职位约10年。他的职业生涯始于任职Merck公司。Hasija先生在德雷克塞尔大学（Drexel University）获得化学工程学士学位，并在纽约大学斯特恩商学院（New York University’s Stern School of Business）获得工商管理硕士学位。
Amit Hasija has served as our Chief Financial Officer and Executive Vice President of Corporate Development, since September 2019. Prior to Milestone Pharmaceuticals, Mr. Hasija served as Chief Financial Officer and Chief Business Officer at Fulcrum Therapeutics. Prior to Fulcrum, he spent five years at Sanofi, most recently serving as Vice President of Integrated Care. At Sanofi, he also served as Vice President of North America Pharmaceutical Business Development. Prior to joining Sanofi over approximately 10 years, Mr. Hasija held positions in investment banking at Credit Suisse, Goldman Sachs and Deutsche Bank. He began his career at Merck. Mr. Hasija received a BS in Chemical Engineering from Drexel University and an MBA from New York University's Stern School of Business.- Amit Hasija自2019年9月起担任公司发展首席财务官兼执行Vice President。在加入Milestone Pharmaceuticals之前，Hasija先生曾担任Fulcrum Therapeutics的首席财务官和首席商务官。任职Fulcrum公司之前，他曾任职Sanofi公司5年，最近担任Integrated Care公司的Vice President。在赛诺菲，他还担任北美制药业务发展的Vice President。在加入赛诺菲之前，Hasija先生在瑞士信贷（Credit Suisse），高盛（Goldman Sachs）和德意志银行（Deutsche Bank）担任投资银行职位约10年。他的职业生涯始于任职Merck公司。Hasija先生在德雷克塞尔大学（Drexel University）获得化学工程学士学位，并在纽约大学斯特恩商学院（New York University’s Stern School of Business）获得工商管理硕士学位。
- Amit Hasija has served as our Chief Financial Officer and Executive Vice President of Corporate Development, since September 2019. Prior to Milestone Pharmaceuticals, Mr. Hasija served as Chief Financial Officer and Chief Business Officer at Fulcrum Therapeutics. Prior to Fulcrum, he spent five years at Sanofi, most recently serving as Vice President of Integrated Care. At Sanofi, he also served as Vice President of North America Pharmaceutical Business Development. Prior to joining Sanofi over approximately 10 years, Mr. Hasija held positions in investment banking at Credit Suisse, Goldman Sachs and Deutsche Bank. He began his career at Merck. Mr. Hasija received a BS in Chemical Engineering from Drexel University and an MBA from New York University's Stern School of Business.